Detalhe da pesquisa
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439329
2.
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry.
Hematol Oncol
; 42(1): e3240, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38050405
3.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38818978
4.
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.
Ann Hematol
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38805036
5.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608183
6.
Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?
Int J Cancer
; 148(7): 1616-1624, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33038278
7.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
8.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499575
9.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137
10.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474619
11.
The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Eur J Haematol
; 105(1): 3-15, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145037
12.
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Eur J Haematol
; 105(3): 286-291, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365249
13.
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Haematologica
; 104(8): 1589-1596, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819917
14.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol
; 37(4): 418-423, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985017
15.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30892724
16.
Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study.
Ann Hematol
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702445
17.
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.
Ann Hematol
; 103(1): 351-355, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37782371
18.
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Ann Hematol
; 98(8): 1885-1890, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044260
19.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30515542
20.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392461